Dyne Therapeutics, Inc. (Nasdaq: DYN) has priced an upsized public offering of 18,300,000 shares of common stock at $20.50 per share, according to a press release issued July 21, 2026.

The gross proceeds from the offering are expected to total $375,150,000 before deducting underwriting discounts, commissions, and other expenses. All shares are being sold by the company.

The offering is expected to close on or about July 23, 2026, subject to customary closing conditions. Dyne has also granted underwriters a 30-day option to purchase up to an additional 2,745,000 shares at the public offering price, less underwriting discounts and commissions.

Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, and Raymond James are acting as joint book-running managers for the offering. Jones is acting as lead manager.

The offering is being made pursuant to a shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission on March 5, 2024.

Dyne Therapeutics is a clinical-stage company developing therapeutics targeting muscle and the central nervous system for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1.